Clinical Trial: Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma
Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Condition: Esophageal Squamous Cell Carcinoma
Study Type: Interventional
Official Title: Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma: A Multi-Centre, Open-Label, Randomized, Controlled, Clinical Trial (HCHTOG2203)
Brief Summary:
No adjuvant treatment has been established for patients who remain at high risk for recurrence after neoadjuvant chemotherapy plus surgery and incidental pathologic lymph node metastasis following initial surgery for esophageal squamous cell carcinoma (ESCC).Controversy still exists regarding the role of adjuvant immunotherapy for ESCC patients who do not achieve pCR after neoadjuvant chemotherapy plus surgery and clinical T1-2 N0 patients with incidental pathologic lymph node metastasis following initial surgery.…
Read more